The objective of the research is to evaluate the regional level management of NAD (home artificial nutrition), the presence of PDTAs for Chronic Inflammatory Intestinal Diseases (IBDs), and supplies of FSMPs.
Despite the clinical and economic benefits associated with clinical nutrition, the study confirms a significant inhomogeneity in the nutritional intake
nutrition of patients with MICI at the regional level, intra-regional
and among different care settings (hospital, home, RSA).
The heterogeneity in access to ONS (oral nutritional supplements) underscores
the urgency of an abatement of differences through national legislation, ensuring equity in the care of patients with MICI throughout the territory.
Authors
Emilia Falcone, Pharmacist Referent SINuC - Italian Society of Clinical Nutrition and Metabolism; ASC Metabolic Diseases, Malnutrition and Clinical Nutrition - SIFO Italian Society of Hospital Pharmacy and Pharmaceutical Services of Health Authorities
Elena Lanati, CEO & Founder Lionhealth Benefit Society
Edoardo Sanna, start up consultant Indicon Benefit Company
Francesca Vinciguerra, senior science manager Lionhealth S.r.l. Benefit Society (SB)
Vincenzo Vivacqua, junior consultant Indicon Benefit Society
